BioVie Inc., a clinical-stage company focusing on developing treatments for neurological and neurodegenerative disorders as well as advanced liver disease, has announced a public offering of 2,667,000 shares of its Class A common stock. The shares are being offered at a price of $2.25 per share. Concurrently, BioVie is offering warrants to purchase up to an additional 2,667,000 shares of common stock. Each warrant has an exercise price of $2.12 per share and is exercisable six months after issuance, with a term of five years from the initial exercise date. The offering is expected to close on or about October 24, 2024, subject to customary closing conditions. ThinkEquity LLC is acting as the exclusive placement agent for the offering. The placement agent has agreed to...Show More

BioVie Inc., a clinical-stage company focusing on developing treatments for neurological and neurodegenerative disorders as well as advanced liver disease, has announced a public offering of 2,667,000 shares of its Class A common stock. The shares are being offered at a price of $2.25 per share. Concurrently, BioVie is offering warrants to purchase up to an additional 2,667,000 shares of common stock. Each warrant has an exercise price of $2.12 per share and is exercisable six months after issuance, with a term of five years from the initial exercise date. The offering is expected to close on or about October 24, 2024, subject to customary closing conditions. ThinkEquity LLC is acting as the exclusive placement agent for the offering. The placement agent has agreed to use its reasonable best efforts to arrange for the sale of the securities offered. BioVie has agreed to pay the placement agent fees as set forth in the table provided in the announcement. The company's common stock is traded on The Nasdaq Capital Market under the symbol 'BIVI.' As of October 23, 2024, the closing price for BioVie's common stock was reported at $2.57 per share. The proceeds from the sale of the securities will be used for working capital and general corporate purposes.